United Therapeutics revenue and financials
In the fiscal year ended December 2025, United Therapeutics reported revenue of $3.18B (+10.61% year over year). Net income was $1.33B, a net margin of 41.9%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +10.61%
- 2025 vs 2024
- Net income growth
- +11.68%
- 2025 vs 2024
- Net margin
- 41.9%
- 2024: 41.5%
How United Therapeutics is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 16.5% a year on average over the last 5 years
Compound annual growth rate: from $1.48B in 2020 to $3.18B in 2025.
Revenue has grown for 6 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin fell from 50.6% to 46.9%
Operating income over revenue, 2022 → 2025: 3.7 percentage points.
Free cash flow equal to 82% of net income
Totals for fiscal years 2023–2025: free cash flow $2.87B, net income $3.51B.
Shares outstanding up 7.4% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 3,183 | 2,877 | 2,328 | 1,936 | 1,686 | 1,483 | 1,449 | 1,628 | 1,725 | 1,599 |
| Cost of revenue | 384 | 310 | 258 | 152 | 123 | 108 | 118 | 199 | 106 | 72.7 |
| Gross profit | 2,798 | 2,568 | 2,070 | 1,785 | 1,563 | 1,375 | 1,331 | 1,429 | 1,620 | 1,526 |
| Selling, general and administrative | 731 | 635 | 474 | 473 | 466 | 421 | 335 | 269 | 333 | 319 |
| Research and development | 550 | 481 | 408 | 323 | 540 | 358 | 1,183 | 358 | 265 | 148 |
| Operating income | 1,493 | 1,377 | 1,185 | 980 | 556 | 594 | -188 | 805 | 815 | 1,062 |
| EBIT | 1,517 | 1,452 | 1,188 | 989 | 687 | 596 | -178 | 803 | 1,022 | 1,059 |
| EBITDA | 1,603 | 1,524 | 1,242 | 1,040 | 737 | 646 | -132 | 838 | 1,053 | 1,091 |
| Interest expense | 19.5 | 42.9 | 59.3 | 32.4 | 18.6 | 23.5 | 44.2 | 13.9 | 9.0 | 3.9 |
| Pre-tax income | 1,714 | 1,539 | 1,274 | 951 | 594 | 639 | -165 | 759 | 770 | 1,060 |
| Income tax | 379 | 344 | 290 | 223 | 118 | 124 | -60.5 | 170 | 352 | 347 |
| Net income | 1,335 | 1,195 | 985 | 727 | 476 | 515 | -105 | 589 | 418 | 714 |
| Net income to common shareholders | 1,335 | 1,195 | 985 | 727 | 476 | 515 | -105 | 589 | 418 | 714 |
| Basic EPS | 30.13 | 26.44 | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | 13.54 | 9.50 | 16.29 |
| Diluted EPS | 27.86 | 24.64 | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 | 13.39 | 9.31 | 15.25 |
| Average shares (basic) | 44.3 | 45.2 | 46.8 | 45.5 | 44.9 | 44.2 | 43.8 | 43.5 | 44.0 | 43.8 |
| Average shares (diluted) | 47.9 | 48.5 | 49.7 | 48.5 | 47.3 | 44.6 | 43.8 | 44.0 | 44.9 | 46.8 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 833 | 783 | 782 | 790 | 800 | 799 | 794 | 736 | 749 | 715 | 678 | 615 |
| Cost of revenue | 99.1 | 99.5 | 133 | 103 | 101 | 87.6 | 92.5 | 75.9 | 83.1 | 77.8 | 72.9 | 71.0 |
| Gross profit | 733 | 684 | 648 | 687 | 699 | 711 | 702 | 660 | 666 | 637 | 605 | 544 |
| Selling, general and administrative | 213 | 207 | 184 | 190 | 182 | 191 | 170 | 159 | 154 | 178 | 144 | 131 |
| Research and development | 279 | 146 | 138 | 140 | 128 | 134 | 149 | 134 | 104 | 140 | 104 | 151 |
| Operating income | 241 | 331 | 326 | 357 | 389 | 386 | 383 | 367 | 408 | 320 | 356 | 261 |
| EBIT | 241 | 331 | 326 | 357 | 389 | 386 | 383 | 367 | 408 | 320 | 356 | 261 |
| EBITDA | 268 | 355 | 348 | 380 | 411 | 407 | 403 | 387 | 427 | 339 | 371 | 275 |
| Interest expense | 2.9 | 2.9 | 3.0 | 3.1 | 3.0 | 7.3 | 6.1 | 7.9 | 10.1 | 11.6 | 13.3 | 15.1 |
| Pre-tax income | 373 | 373 | 318 | 444 | 438 | 408 | 424 | 397 | 389 | 355 | 399 | 295 |
| Income tax | 114 | 39.7 | 43.4 | 79.7 | 99.3 | 98.9 | 101 | 95.2 | 79.5 | 77.2 | 92.0 | 78.3 |
| Net income | 259 | 333 | 275 | 364 | 339 | 310 | 322 | 301 | 309 | 278 | 307 | 217 |
| Net income to common shareholders | 259 | 333 | 275 | 364 | 339 | 310 | 322 | 301 | 309 | 278 | 307 | 217 |
| Basic EPS | 6.06 | 7.82 | 6.32 | 8.41 | 7.73 | 6.86 | 7.18 | 6.74 | 6.93 | 6.26 | 6.52 | 4.62 |
| Diluted EPS | 5.71 | 7.27 | 5.82 | 7.70 | 7.16 | 6.41 | 6.63 | 6.18 | 6.39 | 5.85 | 6.17 | 4.35 |
| Average shares (basic) | 42.7 | 42.6 | 43.5 | 43.3 | 43.8 | 45.1 | 44.9 | 44.7 | 44.6 | 44.4 | 47.0 | 47.0 |
| Average shares (diluted) | 45.3 | 45.8 | 47.2 | 47.3 | 47.3 | 48.3 | 48.6 | 48.7 | 48.4 | 47.5 | 49.7 | 49.8 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7,880 | 7,364 | 7,167 | 6,045 | 5,169 | 4,615 | 3,913 | 3,401 | 2,879 | 2,326 |
| Current assets | 3,703 | 3,874 | 3,551 | 3,380 | 2,324 | 2,167 | 1,865 | 1,768 | 1,448 | 1,425 |
| Cash and equivalents | 1,557 | 1,697 | 1,208 | 961 | 895 | 739 | 738 | 669 | 705 | 1,023 |
| Short-term investments | 1,363 | 1,570 | 1,786 | 1,878 | 1,036 | 1,096 | 748 | 747 | 222 | 27.8 |
| Receivables | 350 | 279 | 300 | 290 | 199 | 157 | 151 | 176 | 297 | 215 |
| Inventory | 183 | 158 | 112 | 102 | 93.8 | 86.5 | 93.4 | 101 | 108 | 100 |
| Net property, plant and equipment | 1,730 | 1,222 | 1,045 | 862 | 781 | 732 | 739 | 700 | 546 | 489 |
| Goodwill | 32.3 | 32.3 | 33.7 | 28.0 | 28.0 | 28.0 | 28.0 | 31.5 | 13.7 | 10.3 |
| Other intangible assets | 84.2 | 79.6 | 80.5 | 16.5 | 16.6 | 130 | 130 | 139 | 31.9 | 23.5 |
| Long-term investments | 1,831 | 1,534 | 1,938 | 1,345 | 1,681 | 1,234 | 854 | 443 | 503 | 2.3 |
| Current liabilities | 561 | 738 | 804 | 343 | 305 | 323 | 463 | 277 | 445 | 333 |
| Accounts payable | 7.1 | 6.0 | 5.6 | 4.1 | 3.8 | 4.1 | 9.9 | 23.1 | 8.4 | 8.1 |
| Long-term debt | — | — | 300 | 800 | 800 | 800 | 600 | 250 | 250 | — |
| Total debt | 37.6 | 300 | 700 | 800 | 800 | 800 | 850 | 250 | 250 | — |
| Total liabilities | 784 | 920 | 1,182 | 1,248 | 1,210 | 1,220 | 1,133 | 593 | 758 | 463 |
| Total equity (incl. minority) | 7,096 | 6,444 | 5,985 | 4,797 | 3,959 | 3,395 | 2,780 | 2,789 | 2,102 | 1,851 |
| Retained earnings | 8,557 | 7,222 | 6,027 | 5,042 | 4,315 | 3,839 | 3,325 | 3,435 | 2,846 | 2,434 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7,034 | 7,220 | 6,714 | 7,880 | 7,351 | 7,908 | 7,744 | 7,364 | 7,123 | 6,723 | 6,495 | 7,167 |
| Current assets | 2,880 | 3,484 | 2,872 | 3,703 | 3,494 | 3,827 | 3,940 | 3,874 | 4,000 | 3,620 | 3,249 | 3,551 |
| Cash and equivalents | 1,189 | 1,803 | 1,280 | 1,557 | 1,340 | 1,593 | 1,900 | 1,697 | 1,554 | 1,356 | 1,252 | 1,208 |
| Short-term investments | 879 | 859 | 874 | 1,363 | 1,428 | 1,456 | 1,421 | 1,570 | 1,773 | 1,616 | 1,456 | 1,786 |
| Receivables | 349 | 310 | 312 | 350 | 298 | 379 | 322 | 279 | 342 | 336 | 307 | 300 |
| Inventory | 202 | 194 | 178 | 183 | 177 | 169 | 165 | 158 | 147 | 137 | 120 | 112 |
| Net property, plant and equipment | 2,042 | 1,930 | 1,841 | 1,730 | 1,556 | 1,362 | 1,303 | 1,222 | 1,157 | 1,095 | 1,074 | 1,045 |
| Goodwill | — | — | — | 32.3 | — | — | — | 32.3 | — | — | — | 33.7 |
| Other intangible assets | 115 | 114 | 116 | 84.2 | 117 | 112 | 112 | 79.6 | 112 | 115 | 115 | 80.5 |
| Long-term investments | 1,558 | 1,233 | 1,409 | 1,831 | 1,656 | 1,977 | 1,770 | 1,534 | 1,308 | 1,359 | 1,520 | 1,938 |
| Current liabilities | 624 | 608 | 599 | 561 | 546 | 527 | 722 | 738 | 873 | 832 | 861 | 804 |
| Accounts payable | 520 | 498 | 498 | 7.1 | 468 | 432 | 367 | 6.0 | 364 | 325 | 305 | 5.6 |
| Long-term debt | — | — | — | — | — | — | — | — | — | 100 | 200 | 300 |
| Total debt | — | — | — | 37.6 | — | — | 200 | 300 | 400 | 500 | 600 | — |
| Total liabilities | 758 | 820 | 813 | 784 | 761 | 734 | 937 | 920 | 1,022 | 1,026 | 1,157 | 1,182 |
| Total equity (incl. minority) | 6,276 | 6,400 | 5,901 | 7,096 | 6,590 | 7,174 | 6,807 | 6,444 | 6,101 | 5,697 | 5,338 | 5,985 |
| Retained earnings | 9,423 | 9,165 | 8,832 | 8,557 | 8,193 | 7,854 | 7,544 | 7,222 | 6,921 | 6,612 | 6,334 | 6,027 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,561 | 1,327 | 978 | 803 | 598 | 756 | -207 | 778 | 474 | 644 |
| Depreciation and amortization | 85.6 | 72.5 | 53.2 | 51.3 | 49.9 | 49.9 | 45.9 | 35.9 | 31.0 | 31.6 |
| Capital expenditure | -521 | -247 | -230 | -139 | -121 | -59.3 | -83.7 | -184 | -86.3 | -38.0 |
| Investing cash flow | -551 | 417 | -720 | -812 | -487 | -739 | -335 | -821 | -836 | 48.3 |
| Financing cash flow | -1,150 | -1,255 | -11.9 | 75.4 | 44.8 | -16.9 | 611 | 6.3 | 43.3 | -498 |
| Share repurchases | -1,000 | -1,000 | 0.0 | 0.0 | -10.8 | -3.7 | -2.1 | — | -250 | -500 |
| Debt issued | 200 | 0.0 | 0.0 | 800 | — | — | 800 | 250 | 250 | — |
| Debt repaid | -500 | -400 | -100 | -800 | — | -50.0 | -200 | -250 | — | -8.8 |
| Effect of exchange rates | — | — | — | — | — | — | — | — | 0.2 | -3.0 |
| Net change in cash | -140 | 490 | 247 | 66.4 | 156 | 0.3 | 69.2 | -35.9 | -318 | 191 |
| Free cash flow | 1,041 | 1,081 | 748 | 664 | 477 | — | — | — | — | — |
| Levered free cash flow | 583 | 834 | 613 | 506 | 407 | 669 | -221 | 318 | 617 | 510 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 307 | 314 | 463 | 346 | 562 | 192 | 461 | 341 | 377 | 232 | 377 | 151 |
| Depreciation and amortization | 26.4 | 24.2 | 22.6 | 22.8 | 21.9 | 21.1 | 19.8 | 19.7 | 19.1 | 18.7 | 15.0 | 13.7 |
| Capital expenditure | -181 | -108 | -101 | -173 | -211 | -62.2 | -74.9 | -86.7 | -76.5 | -45.1 | -38.2 | -78.7 |
| Investing cash flow | -511 | 87.5 | 744 | -228 | 141 | -300 | -165 | -123 | -115 | -80.0 | 735 | 42.1 |
| Financing cash flow | -410 | 122 | -1,484 | 98.4 | -956 | -199 | -93.8 | -74.7 | -64.1 | -48.0 | -1,068 | -92.8 |
| Share repurchases | -503 | -0.5 | -1,558 | -0.6 | -1,001 | -5.2 | -15.3 | -0.3 | -0.4 | -0.1 | -1,011 | -0.1 |
| Debt issued | 0.0 | — | — | 0.0 | 0.0 | 200 | — | — | — | — | — | — |
| Debt repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -400 | -100 | -100 | -100 | -100 | -100 | -100 |
| Net change in cash | -614 | 524 | -277 | 217 | -253 | -307 | 203 | 143 | 198 | 104 | 43.8 | 100 |
| Free cash flow | 126 | 206 | 363 | 173 | 352 | 130 | 386 | 255 | 301 | 187 | 338 | 72.0 |
| Levered free cash flow | 61.3 | 70.1 | 267 | 61.5 | 163 | 79.4 | 284 | 216 | 248 | 80.6 | 289 | 92.2 |
Financial statements of similar companies
Companies in the group: same industry, similar size
